Highlights I-Mab Börse Stuttgart

Equities

0VY

US44975P1030

Market Closed - Börse Stuttgart Other stock markets 11:36:56 03/07/2024 am IST			5-day change	1st Jan Change
1.45 ^EUR	-2.68%		-6.29%	-8.59%

06/06	I-Mab Appoints Phillip Dennis as Chief Medical Officer	CI
05/06	I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	05/06	MT
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05/06	CI
Tranche Update on I-Mab's Equity Buyback Plan announced on August 30, 2022.	30/04	CI
Tranche Update on I-Mab's Equity Buyback Plan announced on August 30, 2022.	30/04	CI
Tranche Update on I-Mab's Equity Buyback Plan announced on August 17, 2023.	30/04	CI
I-Mab Completes Business Divestiture in China	03/04	MT
I-mab Biopharma Co., Ltd. completed the acquisition of I-Mab Biopharma Co., Ltd. from I-Mab.	02/04	CI
I-Mab Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	16/02	RE
Biotech firm I-Mab to divest China operations, shift focus to US	07/02	RE
Biotech firm I-Mab to divest China operations	07/02	RE
I-mab Biopharma Co., Ltd. agreed to acquire I-Mab Biopharma Co., Ltd. from I-Mab for $80 million.	07/02	CI
I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy	02/11	CI
I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023	16/23/16	CI
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503	10/23/10	CI
AbbVie Terminates $3 Billion Cancer Drug Deal With Biotech Firm I-Mab	26/23/26	MT
I-Mab Regains Global Rights to Lemzoparlimab	23/23/23	CI
I-Mab 's Equity Buyback announced on August 23, 2022 has expired with repurchase of 1,960,638 shares, representing 2.36% for $6.8 million.	11/23/11	CI
Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday	31/23/31	MT
I-Mab announces an Equity Buyback for $40 million worth of its shares.	17/23/17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights I-Mab Börse Stuttgart

Equities

0VY

US44975P1030

Highlights

Filters